Mineralys Therapeutics, Inc. (MLYS)
20.93
+0.63
(+3.10%)
USD |
NASDAQ |
Oct 19, 15:49
Mineralys Therapeutics Enterprise Value : 1.230B for Oct. 16, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 16, 2026 | 1.230B |
| October 15, 2026 | 1.348B |
| October 14, 2026 | 1.270B |
| October 13, 2026 | 1.292B |
| October 12, 2026 | 1.400B |
| October 09, 2026 | 1.501B |
| October 08, 2026 | 1.414B |
| October 07, 2026 | 1.388B |
| October 06, 2026 | 1.376B |
| October 05, 2026 | 1.495B |
| October 02, 2026 | 1.524B |
| October 01, 2026 | 1.532B |
| September 30, 2026 | 1.656B |
| September 29, 2026 | 1.599B |
| September 28, 2026 | 1.701B |
| September 25, 2026 | 1.721B |
| September 24, 2026 | 1.785B |
| September 23, 2026 | 1.812B |
| September 22, 2026 | 2.034B |
| September 21, 2026 | 1.937B |
| September 18, 2026 | 1.912B |
| September 17, 2026 | 1.908B |
| September 16, 2026 | 1.869B |
| September 15, 2026 | 1.990B |
| September 14, 2026 | 1.994B |
| Date | Value |
|---|---|
| September 11, 2026 | 1.928B |
| September 10, 2026 | 2.025B |
| September 09, 2026 | 2.131B |
| September 08, 2026 | 2.186B |
| September 04, 2026 | 1.929B |
| September 03, 2026 | 1.934B |
| September 02, 2026 | 2.002B |
| September 01, 2026 | 1.695B |
| August 31, 2026 | 1.704B |
| August 28, 2026 | 1.698B |
| August 27, 2026 | 1.734B |
| August 26, 2026 | 1.724B |
| August 25, 2026 | 1.763B |
| August 24, 2026 | 1.669B |
| August 21, 2026 | 1.702B |
| August 20, 2026 | 1.711B |
| August 19, 2026 | 1.817B |
| August 18, 2026 | 1.787B |
| August 17, 2026 | 1.738B |
| August 14, 2026 | 1.702B |
| August 13, 2026 | 1.741B |
| August 12, 2026 | 1.826B |
| August 11, 2026 | 1.851B |
| August 10, 2026 | 1.855B |
| August 07, 2026 | 1.853B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 7.664B |
| Oncolytics Biotech, Inc. | 58.41M |
| Sangamo Therapeutics, Inc. | 37.40M |
| Sarepta Therapeutics, Inc. | 2.064B |
| Anixa Biosciences, Inc. | 77.38M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -241.07M |
| Total Expenses (Quarterly) | 241.07M |
| EPS Diluted (Quarterly) | -2.845 |
| Earnings Yield | -20.28% |
| Normalized Earnings Yield | -20.27 |